Two Sigma Securities Has Upped Bluebird Bio (BLUE) Position By $968,625; TiVo (TIVO) Covered By 5 Bulls

December 2, 2017 - By Vivian Currie

Two Sigma Securities Llc increased Bluebird Bio Inc (BLUE) stake by 275.95% reported in 2017Q2 SEC filing. Two Sigma Securities Llc acquired 9,225 shares as Bluebird Bio Inc (BLUE)’s stock rose 6.94%. The Two Sigma Securities Llc holds 12,568 shares with $1.32M value, up from 3,343 last quarter. Bluebird Bio Inc now has $7.84B valuation. The stock decreased 0.98% or $1.7 during the last trading session, reaching $171.1. About 633,825 shares traded. bluebird bio, Inc. (NASDAQ:BLUE) has risen 112.34% since December 2, 2016 and is uptrending. It has outperformed by 95.64% the S&P500.

Among 10 analysts covering TiVo (NASDAQ:TIVO), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. TiVo had 20 analyst reports since September 8, 2015 according to SRatingsIntel. The stock of TiVo Corporation (NASDAQ:TIVO) has “Buy” rating given on Wednesday, November 25 by M Partners. Cowen & Co maintained it with “Buy” rating and $30.0 target in Thursday, September 7 report. On Tuesday, August 1 the stock rating was maintained by B. Riley & Co with “Buy”. The rating was downgraded by Barrington Research on Wednesday, November 25 to “Mkt Perform”. The stock of TiVo Corporation (NASDAQ:TIVO) earned “Buy” rating by Topeka Capital Markets on Tuesday, September 8. As per Wednesday, June 1, the company rating was downgraded by M Partners. The stock has “Buy” rating by Jefferies on Friday, August 11. Piper Jaffray maintained it with “Buy” rating and $25.0 target in Friday, November 3 report. The rating was downgraded by Albert Fried to “Market Perform” on Monday, May 2. The firm has “Hold” rating by Topeka Capital Markets given on Monday, May 2. See TiVo Corporation (NASDAQ:TIVO) latest ratings:

09/11/2017 Broker: FBR Capital Rating: Buy New Target: $31.0
03/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $25.0 Maintain
30/10/2017 Broker: B. Riley & Co Rating: Buy New Target: $31.0 Maintain
27/10/2017 Broker: Jefferies Rating: Buy New Target: $18.0 Maintain
20/09/2017 Broker: Jefferies Rating: Buy New Target: $18.0 Maintain
07/09/2017 Broker: Cowen & Co Rating: Buy New Target: $30.0 Maintain
11/08/2017 Broker: Jefferies Rating: Buy New Target: $18.0000 Maintain
04/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $25.0000 Maintain
01/08/2017 Broker: B. Riley & Co Rating: Buy New Target: $31.0000 Maintain
07/07/2017 Broker: Jefferies Rating: Buy New Target: $18.0000 Maintain

Two Sigma Securities Llc decreased Blackrock Inc (NYSE:BLK) stake by 1,525 shares to 1,976 valued at $835,000 in 2017Q2. It also reduced Vereit Inc stake by 44,784 shares and now owns 25,069 shares. Ishares Tr (LQD) was reduced too.

Investors sentiment increased to 1.68 in Q2 2017. Its up 0.68, from 1 in 2017Q1. It improved, as 21 investors sold BLUE shares while 53 reduced holdings. 50 funds opened positions while 74 raised stakes. 47.91 million shares or 5.30% more from 45.50 million shares in 2017Q1 were reported. Strs Ohio accumulated 7,400 shares. Fairfield Bush & Com holds 2,000 shares. Advisory Research, a Illinois-based fund reported 28,050 shares. Tudor Investment Et Al holds 4,149 shares. Tiverton Asset Mgmt Limited Company holds 29,178 shares. California State Teachers Retirement Systems, California-based fund reported 79,540 shares. 44,923 are held by Van Eck Associate Corporation. Parametrica Mngmt Limited has 6,235 shares for 0.61% of their portfolio. Profund Advsr Ltd reported 16,681 shares. Frontier has invested 0.05% in bluebird bio, Inc. (NASDAQ:BLUE). Jennison Assocs Limited Liability Company has invested 0.09% in bluebird bio, Inc. (NASDAQ:BLUE). Cormorant Asset Limited Liability Corporation holds 275,000 shares. The France-based Axa has invested 0.03% in bluebird bio, Inc. (NASDAQ:BLUE). Raymond James & Assoc invested in 0% or 1,975 shares. Westpac Bk reported 0% in bluebird bio, Inc. (NASDAQ:BLUE).

Among 23 analysts covering bluebird bio (NASDAQ:BLUE), 14 have Buy rating, 2 Sell and 7 Hold. Therefore 61% are positive. bluebird bio had 68 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Overweight” rating on Thursday, November 2 by Barclays Capital. Maxim Group maintained the shares of BLUE in report on Friday, June 2 with “Buy” rating. Wells Fargo maintained bluebird bio, Inc. (NASDAQ:BLUE) on Tuesday, October 3 with “Buy” rating. As per Monday, October 30, the company rating was maintained by BMO Capital Markets. The company was downgraded on Friday, October 14 by Cantor Fitzgerald. The firm has “Hold” rating given on Wednesday, October 11 by Jefferies. Morgan Stanley maintained it with “Equal-Weight” rating and $105 target in Monday, August 7 report. BMO Capital Markets upgraded the stock to “Outperform” rating in Tuesday, June 6 report. The firm earned “Buy” rating on Thursday, September 22 by Roth Capital. The firm earned “Buy” rating on Thursday, November 5 by TH Capital.